(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 May 2011 (12.05.2011)

PCT

(10) International Publication Number
WO 2011/056793 A2

(51) International Patent Classification:
A61K 38/17 (2006.01) *A61K 9/08* (2006.01)
A61K 38/16 (2006.01) *A61P 1/16* (2006.01)
A61K 31/195 (2006.01) *A61P 1/00* (2006.01)
A61K 31/185 (2006.01)

(21) International Application Number:
PCT/US2010/055135

(22) International Filing Date:
2 November 2010 (02.11.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/257,711 3 November 2009 (03.11.2009) US

(71) Applicant *(for all designated States except US)*: **TALECRIS BIOTHERAPEUTICS, INC.** [US/US]; 4101 Research Commons, 79 T.W. Alexander Drive, Research Triangle Park, NC 27709 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **GUO, Jianxin** [US/US]; 168 Hudson Lane, Clayton, NC 27527 (US). **KLOS, Anthony** [US/US]; 811 Beaver Dam Road, Raleigh, NC 27607 (US). **COLDREN, Bret** [US/US]; 4101 Research Commons, 79 T.W. Alexander Drive, Research Triangle Park, NC 27709 (US). **BARNETTE, Deborah** [US/US]; 200 Bonniewood Drive, Cary, NC 27518 (US). **MANNING, Mark** [US/US]; 4101 Research Commons, 79 T.W. Alexander Drive, Research Triangle Park, NC 27709 (US).

(74) Agent: **MASSEY, Carl, B.**; Womble Carlyle Sandridge & Rice, PLLC, P.O. Box 7037, Atlanta, GA 30357 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ,

[Continued on next page]

(54) Title: COMPOSITION, METHOD, AND KIT FOR ALPHA-1 PROTEINASE INHIBITOR

(57) Abstract: The present invention provides compositions comprising API and at least one amino acid, in particular a liquid API formulation comprising amino acids, and methods and kits related thereto. These amino acids when incorporated into the API composition afford stability to the API formulation.




FIG. 1

WO 2011/056793 A2

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*